Abstract
MN1-TEL is the product of the recurrent t(12;22)(p12;q11) associated with human myeloid malignancies. MN1-TEL functions as an activated transcription factor, exhibiting weak transforming activity in NIH3T3 fibroblasts that depends on the presence of a functional TEL DNA-binding domain, the N-terminal transactivating sequences of MN1 and C-terminal sequences of MN1. We determined the transforming activity of MN1-TEL in mouse bone marrow (BM) by using retroviral transfer. MN1-TEL-transduced BM showed increased self-renewal capacity of primitive progenitors in vitro, and prolonged in vitro culture of MN1-TEL-expressing BM produced immortalized myeloid, interleukin (IL)-3/stem cell factor-dependent cell lines with a primitive morphology. Transplantation of such cell lines into lethally irradiated mice rescued them from irradiation-induced death and resulted in the contribution of MN1-TEL-expressing cells to all hematopoietic lineages, underscoring the primitive nature of these cells and their capacity to differentiate in vivo. Three months after transplantation, all mice succumbed to promonocytic leukemia. Transplantation of freshly MN1-TEL-transduced BM into lethally irradiated mice also caused acute myeloid leukemia within 3 months of transplantation. We infer that MN1-TEL is a hematopoietic oncogene that stimulates the growth of hematopoietic cells, but depends on secondary mutations to cause leukemia in mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bohlander SK . ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005; 15: 162–174.
Rubnitz JE, Pui CH, Downing JR . The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13: 6–13.
Golub TR, Barker GF, Lovett M, Gilliland DG . Fusion of PDGF receptor beta to a novel ETS-like gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307–316.
Sharrocks AD, Brown AL, Ling Y, Yates PR . The ETS-domain transcription factor family. Int J Biochem Cell Biol 1997; 29: 1371–1387.
Jousset C, Carron C, Boureux A, TranQuang C, Oury C, Dusanter-Fourt I et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRb oncoprotein. EMBO J 1997; 16: 69–82.
Kwiatkowski B, Bastian L, Bauer T, Tsai S, Zielinska-Kwiatkowska A, Hickstein D . The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity. J Biol Chem 1998; 273: 17525–17530.
Potter M, Buijs A, Kreider B, Rompaey LV, Grosveld G . Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. Blood 2000; 95: 3341–3348.
Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J . TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999; 274: 30132–30138.
Chakrabarti SR, Nucifora G . The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 1999; 264: 871–877.
Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 1999; 19: 6566–6574.
Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD et al. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol 2000; 20: 9281–9293.
Szymczyna BR, Arrowsmith CH . DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein–DNA recognition. J Biol Chem 2000; 275: 28363–28370.
Rowley JD . The role of chromosome translocations in leukemogenesis. Semin Hematol 1999; 36: 59–72.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM . The novel activation of ABL by fusion to an ETS-related gene. Cancer Res 1995; 55: 34–38.
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278: 1309–1312.
Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P et al. The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood 1999; 94: 4370–4373.
Knezevich S, McFadden D, Tao W, Lim J, Sorensen P . A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184–187.
Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367–376.
Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891–3999.
Golub TR, Barker GF, Stegmaier K, Gilliland DG . Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol 1996; 211: 279–288.
Liu Q, Schwaller J, Kutok J, Cain D, Aster JC, Williams IR et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 2000; 19: 1827–1838.
Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998; 17: 5321–5333.
Sjoblom T, Boureux A, Ronnstrand L, Heldin CH, Ghysdael J, Ostman A . Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein. Oncogene 1999; 18: 7055–7062.
Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 1999; 93: 1707–1714.
Fears S, Gavin M, Zhang D, Hetherinton C, Ben-David Y, Rowley J et al. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc Natl Acad Sci USA 1997; 94: 1949–1954.
Fenrick R, Hiebert SW . Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 1998; 30–31: 194–202.
Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349–1355.
Nucifora G . The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022–2031.
Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). Blood 1999; 93: 1025–1031.
Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001; 61: 5374–5377.
Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001; 61: 4666–4670.
Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11–q12;p13). Blood 1999; 94: 1820–1824.
Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 1995; 10: 1521–1528.
van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons A et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 2003; 22: 699–709.
Kawagoe H, Grosveld GC . Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood 2005; 106: 4269–4277.
Kawagoe H, Grosveld GC . MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. Blood 2005; 106: 4278–4286.
Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S et al. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. MCB 2005; 25: 2395–2405.
Carella C, Potter M, Bonten J, Rehg JE, Neale G, Grosveld GC . The ETS factor TEL2 is a hematopoietic onco-protein. Blood 2005; 107: 1124–1132.
Goodell MA, McKinney-Freeman S, Camargo FD . Isolation and characterization of side population cells. Methods Mol Biol 2005; 290: 343–352.
Burroughs J, Gupta P, Blazar BR, Verfaillie CM . Diffusible factors from the murine cell line M2–10B4 support human in vitro hematopoiesis. Exp Hematol 1994; 22: 1095–1101.
Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR . Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63–74.
Lavau C, Szilvassy SJ, Slany R, Cleary ML . Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226–4237.
Boisvert FM, Cote J, Boulanger MC, Richard S . A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003; 2: 1319–1330.
Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM et al. A transcriptional switch mediated by cofactor methylation. Science 2001; 294: 2507–2511.
Acknowledgements
We thank Blake McGourty for the supply of C57BL/6/129svJ-mixed background mice and technical assistance. We gratefully acknowledge Ann-Marie Hamilton Easton and Richard Ashmun for expert FACS analysis, and we thank Charlette Hill for editing the manuscript. We are grateful to Luc van Rompaey who initiated these experiments. This work was supported by NCI Grant CA72999, the cancer center (CORE) support grant CA217G and by the American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carella, C., Bonten, J., Rehg, J. et al. MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice. Leukemia 20, 1582–1592 (2006). https://doi.org/10.1038/sj.leu.2404298
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404298
Keywords
This article is cited by
-
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia
Leukemia (2010)
-
Disruption of ETV6 in intron 2 results in upregulatory and insertional events in childhood acute lymphoblastic leukaemia
Leukemia (2008)
-
The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription
Oncogene (2007)